You are here

Article Text

Article menu
Download PDFPDF
DTB Select
Licensing update: classification of glucosamine products

https://doi.org/10.1136/dtb.2019.000019

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Review of: Medicines and Healthcare products Regulatory Agency (MHRA) review of glucosamine-containing products.

    Key learning points

    • Products that contain base glucosamine at 1178 mg/day or higher cannot be sold without a marketing authorisation.

    • Products containing less than 1178 mg/day of glucosamine will continue to be available as food supplements.

    • The Medicines and Healthcare products Regulatory Agency has advised that affected products should be removed from counter and dispensary shelves to avoid the inadvertent sale or supply of unauthorised medicinal products.

    Products containing doses equal to or greater than 1178 mg/day of base glucosamine are now considered to be medicines and cannot be sold without marketing authorisation.1

    Overview

    The Medicines and Healthcare products Regulatory Agency …

    View Full Text

    Footnotes

    • Contributors: DTB Team.

    • Competing interests Commissioned; internally peer reviewed.